Vancouver, British Columbia – November 4, 2025
Rise Health Nano Optics Inc. (“Rise” or the “Company”), a pioneering force in health technology with a focus on innovative nano-optic solutions, proudly announces the issuance of its third U.S. technology patent – U.S. Patent No. 12,383,955 (B2).
This landmark achievement fortifies the Company’s proprietary dominance in advanced materials aimed at eye protection. As a frontrunner in integrating nanotechnology within the eyewear sector, Rise distinguishes itself as the first entity to fully incorporate light-filtering nanoparticle solutions into a fully operational lens manufacturing facility.
Patent Summary
The newly-sanctioned patent, entitled “Products Using Gold and Silver Nanoparticles and Ions to Absorb Visible and UV Light,” encompasses Rise’s exclusive nano-structured lens design that adeptly filters detrimental blue light within the 400-600 nm range and ultraviolet (UV) light, while ensuring optimum visual clarity and color fidelity.
This cutting-edge technology utilizes a meticulously engineered nanoparticle complex that facilitates adaptive spectral filtering without compromising natural vision. It offers enduring protection against wavelengths implicated in retinal oxidative stress, digital eye strain, and longitudinal degenerative injuries.
The patent further enhances Rise’s existing portfolio, safeguarding its EYEGUARD lens platform, which amalgamates nanomaterial ingenuity, ophthalmic research, and scalable optical engineering to deliver secure, high-performance vision protection for both clinical environments and consumer markets.
“Securing our third U.S. patent signals a significant milestone in Rise’s commitment to revolutionizing preventative eye care through cutting-edge nanotechnology. With this new patent, we bolster our technology’s protection and persist in executing our intellectual property strategy effectively,” remarked Inas Said, Founder and CEO of Rise Nano Optics.
“This accomplishment not only solidifies our leadership in optical innovation but also propels us further along the commercialization trajectory. With our strategic market entry and imminent public listing, we are poised to introduce our patented EYEGUARD technology to millions globally—safeguarding vision, enhancing comfort, and creating long-term value for our stakeholders.”
Strategic Outlook and Commercialization
In light of a successful FDA Class I exempt classification and the completion of biocompatibility testing earlier this year, Rise is now diligently preparing for U.S. product registration and market entry.
The Company anticipates commencing North American commercialization in the fourth quarter of 2025, coinciding with its projected public listing on the Canadian Securities Exchange (“CSE”) under the ticker symbol “EYE.”
This strategic initiative aims to facilitate access to growth capital and broaden Rise’s investor base while scaling production and extending distribution within the burgeoning US$160 billion global eyewear market.
About Rise Health Nano Optics Inc.
Rise is an avant-garde health technology firm specializing in nano-optic solutions that combat preventable vision stress and ocular diseases.
Its patented EYEGUARD technology occupies a pivotal intersection of innovation, preventative care, and consumer health, targeting the expansive global eyewear market with substantial relevance to various degenerative eye ailments, diabetes-related vision impairments, and the rapidly expanding wellness wearables industry.
Cautionary Statements
This press release contains “forward-looking statements or information.” Such statements can be identified by terms such as: anticipate, intend, plan, goal, seek, believe, project, estimate, expect, strategy, future, likely, may, should, will, among others.
Examples of forward-looking statements in this release include those regarding the Company’s expected future plans, objectives, and overall expectations.
Forward-looking statements do not constitute historical facts or guarantees of future performance. Instead, they are based solely on our current beliefs, expectations, and assumptions regarding the future of our business, planned strategies, anticipated events, trends, and other conditions.
Due to the inherent uncertainties associated with forward-looking statements, actual results may diverge substantially from those indicated. Therefore, reliance on any such statements is not advised. The Company may not fulfill its projected plans or expectations as articulated.
These statements stem from key assumptions made by the Company, and potential factors that could cause results to vary significantly include, but are not limited to, cash flow adequacy, availability of financing, regulatory developments, consumer perceptions of our products, governmental regulations, competitive landscape, loss of critical personnel, and prevailing economic conditions.
All forward-looking statements are based on information available at the time of publication and speak solely as of that date. Unless required by law, the Company does not undertake any obligation to update these statements publicly, as new information becomes available, or developments occur.
Source link: Finance.yahoo.com.
